Innovent prepares NDA as anti-PCSK9 antibody stars in trials

18 February 2022

Chinese biopharma firm Innovent Biologics (HKEX: 01801) has announced that its experimental anti-PCSK9 antibody, named IBI306, has come up trumps in two Phase III trials in China.

The primary endpoint was met in the CREDIT-1 study of non-familiar hypercholesterolemia (non-FH) patients at high or very high cardiovascular risk and the CREDIT-4 trial of people with hypercholesterolemia including non-FH and heterozygous familial hypercholesterolemia (HeFH).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK